Innovus, Elis finalize Zestra agreement
Innovus Pharmaceuticals and Elis Pharmaceuticals have finalized a second exclusive license and distribution agreement for Zestra. Read More »
Innovus Pharmaceuticals and Elis Pharmaceuticals have finalized a second exclusive license and distribution agreement for Zestra. Read More »
The National Pharmaceutical Council Board of Directors has appointed Dr. Joshua Ofman as its new vice chairman. Read More »
ACADIA Pharmaceuticals' ENHANCE-1 Phase III trial involving pimavanserin has been initiated to assess the ability of pimavanserin to treat schizophrenia in patients who have had a negative response to the antipsychotic therapies currently in use. Read More »
Anthera Pharmaceuticals' Phase 2 BRIGHT-SC trial data has been selected as a poster presentation at the 2016 American Society of Nephrology’s Kidney Week Annual Meeting. Read More »
Amgen's results of its Phase 3 coronary intravascular imaging trial, call GLAGOV, will be presented at the American Heart Association Scientific Sessions 2016. Read More »
ACADIA Pharmaceuticals' Phase II SERENE trial involving pimavanserin has begun. Read More »
ACADIA Pharmaceuticals has started its Phase II clinical trial of pimavanserin called SERENE to assess the medication’s ability to treat patients who have Alzheimer’s disease and are experiencing agitation. Read More »
Tyr Pharma's Resolaris has been granted Fast Track designation by the Food and Drug Administration. Read More »
Cidara Therapeutics' data from its CD101 preclinical and clinical trials was presented at the 2016 American College of Clinical Pharmacy annual meeting and at the IDWeek 2016 meeting last month. Read More »
Eiger BioPharmaceuticals' hepatitis delta campaign has been launched across the country. Read More »
Amgen's Phase 3 clinical trial to assess XGEVA compared to zoledronic acid has achieved its primary goal of proving to delay the time to the first skeletal-related event on-study for multiple myeloma patients. Read More »
CymaBay Therapeutics will present results of its Phase 2 proof-of-concept MBX-8025 clinical trial at the Annual Meeting of the American Association for the Study of Liver Diseases Nov. 11-15 in Boston. Read More »
Arrow Pharmaceuticals intends to give two presentations at The Liver Meeting 2016 on its investigational medicine designed to treat liver disease linked to alpha-1 antitrypsin deficiency, ARC-AAT. Read More »
Perlara PBC, formerly known as Perlstein Lab PBC, has agreed to a drug discovery and development partnership with Novartis that will lead to the identification of new definitive therapeutics for the treatment of lysosomal storage disorders. Read More »
Napo Pharmaceuticals has launched Mytesi, the only medication approved by the U.S. Food and Drug Administration for the relief of diarrhea in patients who have HIV. Read More »
ACADIA Pharmaceuticals has been named the recipient of the 2016 Pantheon DiNA Award by the California Life Sciences Association for its therapeutic product NUPLAZID. Read More »
CymaBay Therapeutics has received a patent to treat NAFLD and NASH with MBX-0825 by administering an amount that proves to be therapeutically effective orally. Read More »
Corvus Pharmaceuticals has released its biomarker findings in its ongoing Phase 1/1b clinical trial involving CPI-444, as both a single agent and as a combination with TECENTRIQ, a Genentech product that is a fully humanized monoclonal antibody developed to target cell death ligand 1 protein. Read More »
Coherus BioSciences has filed of its 351(k) Biologics License Application for its pegfilgrastim biosimilar candidate CHS-1701 has been accepted by the U.S. Food and Drug Administration. Read More »
Kite Pharma has enrolled its first patient into the Phase 1b/2 ZUMA-6 clinical trial involving KTE-C19. Read More »